Hepatic metastases
Updates to Article Attributes
Hepatic metastases are 18-40 times more common than primary liver tumours 6. The most common sites of primary malignancy that seeds to liver are 2:
- gastrointestinal tract (via portal circulation)
- breast cancer
- lung cancer
- genitourinary system
- melanoma
- sarcomas
- essentially all metastatic solid malignancies
Epidemiology
The demographics of patients with liver metastases will mirror that of the underlying primaries, although in general it is safe to say that typically patients are elderly.
Clinical presentation
Liver metastases will usually be asymptomatic and found during work up of a malignancy which has presented in other ways. If metastatic burden is large then presentation, or symptoms related to the liver disease may include:
- localised pain and tenderness due to capsular stretching
- disordered liver metabolic function
- ascites
- low grade fever 2
Radiographic features
The difficulty in imaging the liver for metastatic disease is the high prevalence of benign liver lesions that can be misinterpreted as evidence of metastatic disease, thus dramatically changing a patients stage, and thus treatment options.
Liver haemangiomas, and to a lesser degree FNH are the main sources of confusion 3. Additionally pseudolesions (e.g. transient hepatic attenuation differences (THAD), focal fatty sparing / focal fatty change ) may further murky the waters. Therefore, an understanding of the various appearances of metastatic disease is crucial.
Ultrasound
Routine gray scale ultrasound, contrast enhanced ultrasound and intra-operative ultrasound all have roles to play.
Unfortunately not only do metastases have a wide range of appearances, but echogenicity changes of the liver due to fatty change make absolute statements difficult to make. In general however, metastases may appear as 3:
- rounded and well defined
- positive mass effect with distortion of adjacent vessels
- hypoechoic - most common ~ 65% and is a concerning feature 8
- hypoechoic halo due to compressed and fat spared liver
- cystic, calcified, infiltrative and echogenic appearances are all possible - see liver metastases ultrasound appearances
Contrast enhanced ultrasound has similar characteristics as CT, able to distinguish between hypovascular liver lesions, and hypervascular liver lesions.
CT
The most common appearance of liver metastases is that of hypodense lesions on non-contrast scanning, and demonstrate less enhancement than surrounding liver 1. If there is concomitant hepatic steatosis, then the lesions may be iso or even slightly hyperdense. Enhancement is typically peripheral, and although there may be central filling in on portal venous phase, delayed phase will show washout; helpful in distinguishing metastases from liver haemangiomas 1.
Some primaries have a tendency to produce hyper-enhancing metastases, including RCC, thyroid, neuroendocrine etc.. see hypervascular liver lesions.
MRI
The appearance of liver metastases on MRI is of course also variable, but is more sensitive than CT for the detection of liver metastases 5. MRI examination of the liver may involve numerous sequences; see liver MRI protocol.
Most frequent appearances is 5:
- T1 - moderately hypo intense
- T2 - moderately hyper intense
-
C+ (Gd) - enhancement may be lesional or perilesional 7 (enhancement outside the confines of the T1 delineated lesion)
- small lesions < 1.5cm tend to uniformly enhance.
- larger lesions, > 1.5cm : the most common pattern of enhancement is of transient rim enhancement (i.e. with wash-out); helpful feature in distinguishing a metastasis from a liver haemangioma.
- peri-lesional enhancement is most commonly seen in colorectal and pancreatic adenocarcinoma metastases 5.
Differential diagnosis
General imaging differential considerations include
-
hepatic haemangioma
- usually hyper-echoic
- geographic
- no mass effect
- characteristic peripheral nodular enhancement with gradual 'filling in' 1
-
hepatocellular carcinoma (HCC)
- hyper-vascular
- more frequently solitary
- may also have hypoechoic halo
-
focal nodular hyperplasia (FNH)
- often younger patients
- central scar, with delayed enhancement
- hepatic adenoma
- hepatic peliosis
- pseudolesions
- transient hepatic attenuation differences (THAD)
-
focal fatty sparing / focal fatty change
- characteristic distribution
- lack of mass effect
- cirrhosis
- multiple biliary hamartomas
-</ul><h4>Radiographic features</h4><p>The difficulty in imaging the liver for metastatic disease is the high prevalence of benign liver lesions that can be misinterpreted as evidence of metastatic disease, thus dramatically changing a patients stage, and thus treatment options.</p><p><a href="/articles/hepatic-haemangioma">Liver haemangiomas</a>, and to a lesser degree <a href="/articles/focal-nodular-hyperplasia">FNH</a> are the main sources of confusion <sup>3</sup>. Additionally pseudolesions (e.g. <a href="/articles/transient-hepatic-attenuation-differences">transient hepatic attenuation differences (THAD)</a>, <a href="/articles/focal-fatty-sparing-of-the-liver">focal fatty sparing</a> / <a href="/articles/focal_fat_infiltration">focal fatty change</a> ) may further murky the waters. Therefore, an understanding of the various appearances of metastatic disease is crucial.</p><h5>Ultrasound</h5><p>Routine gray scale ultrasound, contrast enhanced ultrasound and intra-operative ultrasound all have roles to play.</p><p>Unfortunately not only do metastases have a wide range of appearances, but echogenicity changes of the liver due to fatty change make absolute statements difficult to make. In general however, metastases may appear as <sup>3</sup>:</p><ul>- +</ul><h4>Radiographic features</h4><p>The difficulty in imaging the liver for metastatic disease is the high prevalence of benign liver lesions that can be misinterpreted as evidence of metastatic disease, thus dramatically changing a patients stage, and thus treatment options.</p><p><a href="/articles/hepatic-haemangioma">Liver haemangiomas</a>, and to a lesser degree <a href="/articles/focal-nodular-hyperplasia">FNH</a> are the main sources of confusion <sup>3</sup>. Additionally pseudolesions (e.g. <a href="/articles/transient-hepatic-attenuation-differences">transient hepatic attenuation differences (THAD)</a>, <a href="/articles/focal-fatty-sparing-of-the-liver">focal fatty sparing</a> / <a href="/articles/focal-hepatic-steatosis">focal fatty change</a> ) may further murky the waters. Therefore, an understanding of the various appearances of metastatic disease is crucial.</p><h5>Ultrasound</h5><p>Routine gray scale ultrasound, contrast enhanced ultrasound and intra-operative ultrasound all have roles to play.</p><p>Unfortunately not only do metastases have a wide range of appearances, but echogenicity changes of the liver due to fatty change make absolute statements difficult to make. In general however, metastases may appear as <sup>3</sup>:</p><ul>
-</ul><p>Contrast enhanced ultrasound has similar characteristics as CT, able to distinguish between <a href="/articles/hypovascular-liver-lesions">hypovascular liver lesions</a>, and <a href="/articles/hypervascular_liver_lesions">hypervascular liver lesions</a>.</p><h5>CT</h5><p>The most common appearance of liver metastases is that of hypodense lesions on non-contrast scanning, and demonstrate less enhancement than surrounding liver <sup>1</sup>. If there is concomitant hepatic steatosis, then the lesions may be iso or even slightly hyperdense. Enhancement is typically peripheral, and although there may be central filling in on portal venous phase, delayed phase will show washout; helpful in distinguishing metastases from liver haemangiomas <sup>1</sup>.</p><p>Some primaries have a tendency to produce hyper-enhancing metastases, including <a href="/articles/renal-cell-cancer-rcc">RCC</a>, <a href="/articles/follicular-thyroid-cancer">thyroid</a>, neuroendocrine etc.. see <a href="/articles/hypervascular_liver_lesions">hypervascular liver lesions</a>.</p><h5>MRI</h5><p>The appearance of liver metastases on MRI is of course also variable, but is more sensitive than CT for the detection of liver metastases <sup>5</sup>. MRI examination of the liver may involve numerous sequences; see <a href="/articles/liver-mri-protocol">liver MRI protocol</a>.</p><p>Most frequent appearances is <sup>5</sup>:</p><ul>- +</ul><p>Contrast enhanced ultrasound has similar characteristics as CT, able to distinguish between <a href="/articles/hypovascular-liver-lesions">hypovascular liver lesions</a>, and <a href="/articles/hypervascular-liver-lesions">hypervascular liver lesions</a>.</p><h5>CT</h5><p>The most common appearance of liver metastases is that of hypodense lesions on non-contrast scanning, and demonstrate less enhancement than surrounding liver <sup>1</sup>. If there is concomitant hepatic steatosis, then the lesions may be iso or even slightly hyperdense. Enhancement is typically peripheral, and although there may be central filling in on portal venous phase, delayed phase will show washout; helpful in distinguishing metastases from liver haemangiomas <sup>1</sup>.</p><p>Some primaries have a tendency to produce hyper-enhancing metastases, including <a href="/articles/renal-cell-cancer-rcc">RCC</a>, <a href="/articles/follicular-thyroid-cancer">thyroid</a>, neuroendocrine etc.. see <a href="/articles/hypervascular-liver-lesions">hypervascular liver lesions</a>.</p><h5>MRI</h5><p>The appearance of liver metastases on MRI is of course also variable, but is more sensitive than CT for the detection of liver metastases <sup>5</sup>. MRI examination of the liver may involve numerous sequences; see <a href="/articles/liver-mri-protocol">liver MRI protocol</a>.</p><p>Most frequent appearances is <sup>5</sup>:</p><ul>
-<li><a href="/articles/hepatic_adenoma">hepatic adenoma</a></li>- +<li><a href="/articles/hepatic-adenoma">hepatic adenoma</a></li>